Navigation Links
AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
Date:5/19/2009

    Partner Keryx to present Phase 2 data on perifosine for multiple cancers

QUEBEC CITY, May 19 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that results supporting the evaluation of its targeted cytotoxic peptide conjugate compound, AEZS-108, in prostate cancer, will be presented as a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 through June 2, 2009 at the Orange County Convention Center in Orlando, Florida.

AEZS-108

Results presented are important for the expansion of potential indications for AEZS-108. While clinical investigations so far focused on gynaecological indications, the new results show continued expression of Luteinizing Hormone Releasing Hormone (LHRH) receptors in prostate cancer specimens after prolonged use of LHRH agonists; these data provide further support to the investigation of the drug in hormone-refractory prostate cancer, a major genitourinary cancer indication in male patients.

Abstract selected for presentation is as follows:

Genitourinary Cancer

Sunday, May 31, 2009:

# 5103: Expression of LHRH receptors in prostate cancer cells prior to therapy, following castration, or following treatment with LHRH agonists

Lead Author: Stephen Liu, MD

Poster Session: 2 pm - 6 pm (Level 2, West Hall C)

Perifosine

Additionally, AEterna Zentaris' partner, Keryx Biopharmaceuticals, announced yesterday that it will present four posters on the Akt-inhibitor compound, perifosine, during the ASCO meeting. Keryx is currently developing perifosine in multiple Phase 2 trials for various types of cancer. All of the clinical data
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
2. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
3. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
4. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
5. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
6. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
7. AEterna Zentaris to Announce Fourth Quarter and Full-Year 2008 Financial and Operating Results on March 11, 2009
8. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
10. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
11. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Stem cell-enriched autologous fat enables sustainable breast augmentation ... the media: For years a French company has been ... cause cancer. More than 100,000 women worldwide must now ... or carrying a "time bomb" in their bodies. Stem ...
... Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that it will ... the Windsor Room of the Sir Francis Drake Hotel as ... emerging biotech companies held over 3 days this week in ... attendees are expected to be listening to presentations by up ...
... SEATTLE, Jan. 10, 2012  Omeros Corporation (NASDAQ: OMER ... selectively with each of GPR25, GPR32, GPR80, GPR135 and MAS1, ... unlocked by Omeros to 23, representing 30 percent of the ... unlocked by Omeros for drug development equals half of the ...
Cached Biology Technology:Silicone Scandal: Stem Cell Breast Augmentation a Safe Alternative 2NW Bio to Present Today at the OneMedForum SF 2012 Conference 2NW Bio to Present Today at the OneMedForum SF 2012 Conference 3Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs 2Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs 3Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs 4Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs 5
(Date:4/15/2014)... research published in the March/April 2014 issue of ... shows whey protein, either as a supplement combined ... or weight-maintenance diet, may provide men and women benefits ... 14 randomized controlled trials with a total of 626 ... that used whey protein to replace calories in the ...
(Date:4/14/2014)... Rican climate over the past three decades have caused ... territory,s national animal. UCLA biologists have found that not ... call has also become shorter and higher pitched. ... of integrative biology and physiology and of ecology and ... the study examined 170 male coqui frogs ( Eleutherodactylus ...
(Date:4/14/2014)... the International Space Station inside the Dragon capsule ... in-orbit food production capabilities in more ways than ... for granted, fresh food. , NASA,s Veg-01 experiment ... and performance of a new expandable plant growth ... investigation will focus on the growth and development ...
Breaking Biology News(10 mins):New meta-analysis builds on the power of whey protein for improved body composition 2New meta-analysis builds on the power of whey protein for improved body composition 3Climate change a likely culprit in coqui frog's altered calls, say UCLA biologists 2Veggie will expand fresh food production on space station 2
... -- Dangerous disease often spreads faster than it takes ... researchers at Kansas State University have developed a test ... Sanjeev Narayanan, assistant professor, and Greg Peterson, research ... pathobiology, use a device called a DNA spotted microarray ...
... Ackermann and Wolf-Dietrich Hardt, in collaboration with Michael Doebeli ... have been able to describe how random molecular processes ... a self-destructive act to generate a greater common good, ... Survival strategy The biologists investigated this ...
... relapse after renewed drug administration are typical behavioral patterns ... the brain,s reward center are directly responsible for this. ... the Institute of Mental Health (ZI) in Mannheim, the ... University of Geneva, Switzerland, in the latest issue of ...
Cached Biology News:Rapid test for pathogens developed by K-State researchers 2ETH Zurich study on salmonella self-destruction 2ETH Zurich study on salmonella self-destruction 3Cocaine: How addiction develops 2
Anti-ACTH Immunogen: Porcine ACTH conjugated to BSA. Available Date: 38566...
Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
... Immunogen: Peptide ... encompassing the human, mouse, and ... Accession Number: NM_000314 ... Routinely evaluated by immunoblot. ...
Mouse monoclonal [MN-8C4] to zona radiata ( Abpromise for all tested applications). Antigen: Purified eggshell proteins (zona radiata proteins and small amounts of zona pellucida proteins) from ...
Biology Products: